Sivaram P, Vanni-Reyes T, Goldberg I J
Division of Preventive Medicine and Nutrition, Department of Medicine, Columbia University, New York, New York 10032, USA.
J Biol Chem. 1996 Jun 21;271(25):15261-6. doi: 10.1074/jbc.271.25.15261.
We reported previously that a 116-kDa lipoprotein lipase (LPL)-binding protein from endothelial cells has sequence homology to the amino-terminal region of apolipoprotein (apo) B. We now tested whether endothelial cells synthesize apoB mRNA and protein. Primers were designed to the human apoB cDNA sequence and reverse transcription polymerase chain reaction was performed using total RNA isolated from bovine and human endothelial cells. With primers to the 5' region of the apoB mRNA (amino-terminal region of apoB protein) expected size PCR products were generated from both bovine and human endothelial cells as well as from mouse liver RNA, which was used as a control. Primers designed to the 3' region of apoB mRNA generated PCR products from human endothelial cells and HepG2 cells but not from bovine or mouse cells. These data suggest that endothelial cells contain full-length apoB mRNA and that the 5' or the amino-terminal region of apoB is highly conserved from mouse to human. This was confirmed by direct sequencing of the mouse and bovine PCR products. To test whether apoB protein was produced, bovine endothelial cell proteins were metabolically labeled with [35S]methionine/cysteine or [3H]leucine and immunoprecipitated with anti-human apoB antibodies. Using extracts from cells labeled for 1 h, monoclonal antibody 47, directed to the low density lipoprotein receptor binding region of apoB, precipitated a protein of approximate molecular mass 550,000, the size of full-length apoB. Immunoprecipitation of the 550-kDa protein was abolished in the presence of added unlabeled low density lipoprotein. From cells labeled for 16 h, a 116-kDa protein was immunoprecipitated by polyclonal anti-apoB antibodies. This protein was partly released from cells by heparin treatment. Pulse-chase analysis showed that the 116-kDa fragment appeared at the same time as the full-length apoB began disappearing. The immunoprecipitated 116-kDa fragment also bound labeled LPL on ligand blot, further suggesting that it is an amino-terminal fragment of apoB. Incubation of endothelial cells with oleic acid (0.25 and 0.5 mM) did not significantly alter the production of either the full-length apoB or the 116-kDa fragment. These data show that endothelial cells synthesize apoB. The full-length apoB appears to be cleaved to form a 116-kDa fragment that can function as a LPL-binding protein.
我们之前报道过,一种来自内皮细胞的116 kDa脂蛋白脂肪酶(LPL)结合蛋白与载脂蛋白(apo)B的氨基末端区域具有序列同源性。我们现在测试了内皮细胞是否合成apoB mRNA和蛋白质。针对人apoB cDNA序列设计引物,并使用从牛和人内皮细胞分离的总RNA进行逆转录聚合酶链反应。使用针对apoB mRNA 5'区域(apoB蛋白的氨基末端区域)的引物,从牛和人内皮细胞以及用作对照的小鼠肝脏RNA中均产生了预期大小的PCR产物。针对apoB mRNA 3'区域设计的引物从人内皮细胞和HepG2细胞中产生了PCR产物,但未从牛或小鼠细胞中产生。这些数据表明内皮细胞含有全长apoB mRNA,并且apoB的5'或氨基末端区域从小鼠到人类高度保守。通过对小鼠和牛的PCR产物进行直接测序证实了这一点。为了测试是否产生了apoB蛋白,用[35S]甲硫氨酸/半胱氨酸或[3H]亮氨酸对牛内皮细胞蛋白进行代谢标记,并用抗人apoB抗体进行免疫沉淀。使用标记1小时的细胞提取物,针对apoB低密度脂蛋白受体结合区域的单克隆抗体47沉淀出一种分子量约为550,000的蛋白质,即全长apoB的大小。在添加未标记的低密度脂蛋白的情况下,550 kDa蛋白的免疫沉淀被消除。从标记16小时的细胞中,一种116 kDa的蛋白被多克隆抗apoB抗体免疫沉淀。这种蛋白通过肝素处理部分从细胞中释放出来。脉冲追踪分析表明,116 kDa片段与全长apoB开始消失的时间相同出现。免疫沉淀的116 kDa片段在配体印迹上也与标记的LPL结合,进一步表明它是apoB的氨基末端片段。用油酸(0.25和0.5 mM)孵育内皮细胞不会显著改变全长apoB或116 kDa片段的产生。这些数据表明内皮细胞合成apoB。全长apoB似乎被切割形成一个116 kDa的片段,该片段可以作为LPL结合蛋白发挥作用。